Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.
A case-control study in the Netherlands found an almost 3-fold increased CVD risk in those with very high Lp(a) levels. Addition of Lp(a) to risk scores for patients with very high Lp(a) levels resulted in a higher percentage of patients being reclassified.
In this e-learning program, three experts explain why it is important to measure Lp(a) levels. Furthermore, they describe the effects of currently available lipid-lowering treatments on Lp(a) levels and talk about potential therapies for Lp(a) lowering which are currently under investigation.
Prof. Stroes describes the effects of currently available lipid-lowering treatments on Lp(a) levels. Futhermore, he talks about potential RNA-based therapies for Lp(a)-lowering, which are currently under investigation.
Prof. Kronenberg talks about the epidemiology and genetic basis of Lp(a) levels and explains why and when Lp(a) should be measured.
What is Lp(a), how common are high Lp(a) levels and what is the relationship with CV events? Prof. Sattar answers these questions in a brief overview. With poll
EAS 2021 An analysis of data from the German Lipoprotein Apheresis Registry (GLAR) from 2012-2020 demonstrated substantial lowering of MACE and major non-coronary events within two years of initiation of lipoprotein apheresis.
The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.
This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.
This online course covers different aspects of lipoprotein(a) (Lp(a)): the pathophysiology, its role in CVD risk and (novel) therapeutic options to reduce Lp(a) levels. This educational program is chaired by Erik Stroes, MD - Amsterdam, The Netherlands.
A post-hoc analysis of the ODYSSEY OUTCOMES trial found that Lp(a) reduction with alirocumab was, independent of LDL-c reduction, associated with reduced total CV events in ACS patients.
Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.